We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT01239381
Previous Study | Return to List | Next Study

Individualized Stereotactic Body Radiotherapy of Liver Metastases

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01239381
First Posted: November 11, 2010
Last Update Posted: November 6, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Dana-Farber Cancer Institute
Brigham and Women's Hospital
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Theodore Sunki Hong, Massachusetts General Hospital
  Purpose
Stereotactic body radiation therapy (SBRT) is a technique that is used to deliver radiation, to sites in the body. All participants in this study will be treated with SBRT using proton beam radiation. Proton beam radiation uses tiny particles to deliver radiation to tumors. The purpose of this research study is to determine if SBRT with protons will prevent tumor growth and reduce the treatment side effects for liver metastases.

Condition Intervention
Solid Tumor Liver Metastases Radiation: Stereotactic body radiotherapy-proton

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Individualized Stereotactic Body Radiotherapy of Liver Metastases

Further study details as provided by Theodore Sunki Hong, Massachusetts General Hospital:

Primary Outcome Measures:
  • Local Control Rate [ Time Frame: 1 year ]

    The percentage of participants with local control at primary tumor site at one year. Local is evaluated using Response Evaluation Criteria In Solid Tumors (RECIST). Local control is defined as achieving either Complete response (CR), Partial Response (PR), or Stable Disease (SD).

    • (CR): Disappearance of entire lesion, with no additional evidence of disease.
    • (PR): At least a 30% decrease in the (sum of) the longest diameter (LD) of the primary lesion, taken as reference the baseline sum LD.
    • (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.


Secondary Outcome Measures:
  • Median Follow-up Time [ Time Frame: 1 year ]
    The median follow-up time among the 39 participants still alive at the time of analysis, measured from the start of treatment until the time of analysis.

  • Median Overall Survival [ Time Frame: 2 years ]
    The median overall survival (in months) of participants as measured from the start of treatment.

  • Median Progression Free Survival [ Time Frame: 1 years ]
    The median amount of time participants survived without cancer progression following the start of study treatment. Progression was assessed using RECIST v1.0. Progressive Disease (PD) is defined as at least a 20% increase in the Longest Diameter (LD) of the lesion, taken as the reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.

  • 2-year Local Control Rate [ Time Frame: 2 years ]
    The percentage of participants with local control 2 years after the start of study treatment.

  • 1 Year Local Control Rate Among Participants With Colorectal Cancer [ Time Frame: 1 year ]
    The percentage of participants with local control at one year among the participants with colorectal cancer as the primary cancer.

  • Median Survival Among Participants With Colorectal Cancer [ Time Frame: 2 years ]
    The median amount of time participants survived from the start of treatment, among the participants with colorectal cancer.


Enrollment: 92
Study Start Date: June 2010
Study Completion Date: September 2017
Primary Completion Date: January 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SBRT-Proton
Stereotactic body radiotherapy by proton radiation
Radiation: Stereotactic body radiotherapy-proton
Dose will be determined by the size and location of the tumor(s); 2-3 treatments per week for two weeks

Detailed Description:
  • Participants receiving SBRT with protons, will receive radiation treatment as an outpatient at the Francis H. Burr Proton Therapy Center at Massachusetts General Hospital.
  • Not everyone who participates in this study will be receiving the same dose of radiation. The dose received will be determined by the size and location of the tumor(s).
  • Participants will receive 2-3 SBRT treatments per week for two weeks.
  • During radiation therapy visits the following tests/procedures will be performed: vital signs, physical examination, routine blood tests, research blood tests, and radiation planning.
  • Follow-up assessments will be performed once at 9 weeks after study treatment, then at 6 months, 12 months, 18 months and 24 months after treatment.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Biopsy-proven cancer diagnosis of a solid tumor with 1-4 liver metastases. There is no upper size limit. Liver metastases may be diagnosed by imaging alone, no liver biopsy is required. Extrahepatic disease is allowed if it have been stable for 3 months prior to study entry, the dominant disease burden is intrahepatic and the patient is referred for definitive radiation therapy to the disease in the liver
  • Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension as 10mm or greater with spiral CT scan
  • Patients may have had prior chemotherapy, targeted biological therapy, surgery, transarterial chemoembolization (TACE), radiofrequency ablation, or cryosurgery for their disease as long as the prior therapy occured greater than 3 weeks elapsed before the first radiation treatment. Patients may not have had prior liver directed radiation, including radioembolization.
  • 18 years of age or older
  • Expected survival must be greater than three months
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
  • Patients must have at least 800mL of uninvolved liver
  • Normal organ and marrow function as outlined in the protocol
  • If patient has underlying cirrhosis, only Child-Pugh classification Group A patients should be included in this study. Clinical assessment of ascites and encephalopathy is required. Child-Pugh classification must be determined for all study participants at the time of eligibility analysis.
  • Women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation

Exclusion Criteria:

  • Women who are pregnant or lactating
  • Patients with gross ascites or encephalopathy
  • Local conditions or systemic illnesses which would reduce the local tolerance to radiation treatment, such as serious local injuries, active collagen vascular disease, etc.
  • Prior liver directed radiation treatment, including selective internal radiation
  • No serious medical illness, which may limit survival to less than 3 months
  • No serious psychiatric illness which would limit compliance with treatment
  • Participants who have had chemotherapy or radiotherapy within 3 weeks prior to starting study treatment or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier
  • Participants may not be receiving any other investigational agents, or any other anti-cancer therapy during treatment
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia.
  • Only solid tumors are permitted. Thus, individuals with a liver mass from a diagnosis of lymphoma or leukemia are excluded
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01239381


Locations
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Dana-Farber Cancer Institue
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Massachusetts General Hospital
Dana-Farber Cancer Institute
Brigham and Women's Hospital
National Cancer Institute (NCI)
Investigators
Principal Investigator: Theodore S. Hong, MD Massachusetts General Hospital
  More Information

Responsible Party: Theodore Sunki Hong, Attending Radiation Oncologist, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT01239381     History of Changes
Other Study ID Numbers: 10-139
Other ( Other Grant/Funding Number: program income earned on C06 CA059267 )
First Submitted: June 14, 2010
First Posted: November 11, 2010
Results First Submitted: March 24, 2017
Results First Posted: July 13, 2017
Last Update Posted: November 6, 2017
Last Verified: October 2017

Keywords provided by Theodore Sunki Hong, Massachusetts General Hospital:
proton radiation
stereotactic body radiotherapy
SBRT

Additional relevant MeSH terms:
Neoplasm Metastasis
Liver Neoplasms
Neoplastic Processes
Neoplasms
Pathologic Processes
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases